Back to School: How biopharma can reboot drug development. Access exclusive analysis here

V520 HIV-1 gag/pol/nef trivalent vaccine: Phase II discontinued

MRK discontinued vaccination and enrollment in the Phase II STEP trial (HVTN 502, Merck 023) in 3,000 HIV-negative volunteers at high risk of HIV infection following

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE